Literature DB >> 17804564

Circulating CD4+CD25 high regulatory T cells and natural killer T cells in children with newly diagnosed type 1 diabetes or with diabetes-associated autoantibodies.

Viveka Oling1, Jane Marttila, Mikael Knip, Olli Simell, Jorma Ilonen.   

Abstract

Type 1 diabetes is a T-cell-mediated autoimmune disease in which insufficient regulatory mechanisms are perceived to be involved in the pathogenesis. We used flow cytometry to analyze the proportion of CD4(+)CD25(high) regulatory T cells and natural killer T (NKT) cells in peripheral blood obtained from 25 children with newly diagnosed type 1 diabetes, 21 nondiabetic subjects positive for two or more diabetes-associated autoantibodies, and from 39 autoantibody-negative age- and HLA-matched control subjects. CD4(+)CD25(high) T cells were also stained for additional markers HLA-DR, CD69, and CD62L. As NKT cell markers, we used CD161, V beta 11, and V alpha 24. The frequency of CD4(+)CD25(high)HLA-DR(-) T cells was significantly higher in multiple autoantibody-positive children than in controls (P = 0.021). We also detected a significantly higher level of CD4(+)CD25(high)HLA-DR(-) and CD4(+)CD25(high)CD69(-) T cells among children expressing three to four autoantibodies when compared to the controls (P = 0.004 and P = 0.048, respectively). The proportions of CD161(+)V beta 11(+) or V alpha 24(+)V beta 11(+) NKT cells were similar in all three groups of children studied. Interestingly, children with only two autoantibodies had a higher level of CD161(+)V beta 11(+) NKT cells than the controls (P = 0.002). Our data might be interpreted as indicative of an intensified regulatory response of regulatory T cells and NKT cells during the preclinical phase of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804564     DOI: 10.1196/annals.1381.038

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.

Authors:  Tom Erkers; Bryan J Xie; Laura J Kenyon; Brian Smith; Mary Rieck; Kent P Jensen; Xuhuai Ji; Marina Basina; Samuel Strober; Robert S Negrin; Holden T Maecker; Everett H Meyer
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

Review 2.  Prediction and pathogenesis in type 1 diabetes.

Authors:  Anette-G Ziegler; Gerald T Nepom
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

3.  Type I diabetes-associated tolerogenic properties of interleukin-2.

Authors:  Aziz Alami Chentoufi; Simon Gaudreau; Alex Nguyen; Mahmoud Sabha; Abdelaziz Amrani; Geyhad Elghazali
Journal:  Clin Dev Immunol       Date:  2011-05-10

4.  Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression.

Authors:  Gusheng Wu; Zi-Hua Lu; Hans-Joachim Gabius; Robert W Ledeen; David Bleich
Journal:  Diabetes       Date:  2011-07-25       Impact factor: 9.461

Review 5.  iNKT and MAIT Cell Alterations in Diabetes.

Authors:  Isabelle Magalhaes; Badr Kiaf; Agnès Lehuen
Journal:  Front Immunol       Date:  2015-07-02       Impact factor: 7.561

6.  Deranged regulatory T-cells and transforming growth factor-β1 levels in type 1 diabetes patients with associated autoimmune diseases.

Authors:  N Kaur; R W Minz; S K Bhadada; D Dayal; J Singh; S Anand
Journal:  J Postgrad Med       Date:  2017 Jul-Sep       Impact factor: 1.476

Review 7.  Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1.

Authors:  Iwona Ben-Skowronek; Joanna Sieniawska; Emilia Pach; Wiktoria Wrobel; Anna Skowronek; Zaklina Tomczyk; Iga Rosolowska
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.